Evidence map›Paper›PMID 40192997›Full record

ReviewInflammopharmacology2025

Role of guanylate-binding protein 5 in inflammatory diseases, immune diseases, cancers, and its potential therapeutic implications.

Xufan Sun, Guiyuan Jin, Huihui Zhou, Yan Wang, Fengxian Dai, Guangxi Zhou

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Frontiers in pharmacology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xufan SunClinical Medical College of Jining Medical University, Jining Medical University, Jining, People's Republic of China.
Guiyuan JinMedical Research Center, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, People's Republic of China.
Huihui ZhouDepartment of Gastroenterology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, People's Republic of China.
Yan WangDepartment of Gastroenterology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, People's Republic of China.
Fengxian DaiDepartment of Gastroenterology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, People's Republic of China.
Guangxi ZhouDepartment of Gastroenterology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, People's Republic of China. zgx_viola@126.com.ORCID http://orcid.org/0000-0002-7803-605X

Funding

Development plan of Medicine and Health Science and Technology in Shandong Province 202203030672Innovative Research Group Project of the National Natural Science Foundation of China 82270562Tai Shan Young Scholar Foundation of Shandong Province tsqn202103190TCM science and technology development plan of Shandong Province M-2023173
6 · The paper itself

Abstract

Guanylate-binding protein 5 (GBP5) is an interferon-γ (IFN-γ)-induced GTPase (Guanosine Triphosphatease) family member. It contains highly conserved guanosine triphosphate (GTP)-binding and hydrolysis domains, particularly within myeloid and T cells. Extensive research has underscored the critical role of GBP5 in various biological processes, including inflammation, cancer cell migration, and viral defence. In addition, GBP5 is involved in a range of physiological processes and is implicated in various pathological conditions, including inflammation and immune-related disorders. Recent studies have revealed the significant role of GBP5 in the initiation and progression of cancer. The impact of GBP5 on cancer varies depending on the specific cancer type and its underlying mechanisms of action. GBP5 can modulate multiple signalling pathways, including those involved in cell proliferation, cell cycle regulation, invasive metastasis, and the maintenance of homeostasis in vivo, all of which contribute to the progression of cancer. Consequently, in addition to functioning as a downstream molecule in the IFN-γ signalling pathway, GBP5 can influence the onset and progression of various diseases. This article examines the role of GBP5 in inflammation, autoimmune disorders, and malignancies while also exploring its potential therapeutic implications. We aim to deepen our understanding of GBP5 and assess its prospective applications in clinical diagnosis and treatment.

Indexed as

GTP-Binding ProteinsImmune System DiseasesInflammationNeoplasmsAnimalsHumansInterferon-gammaSignal TransductionGTP-Binding ProteinsInterferon-gammaCancersGuanylate-binding protein 5Immune diseasesInflammatory diseasesTherapeutic target

Identifiers

PMID40192997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.